Asset Details
Do you wish to reserve the book?
A meta-analysis of CXCL12 expression for cancer prognosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A meta-analysis of CXCL12 expression for cancer prognosis
Do you wish to request the book?
A meta-analysis of CXCL12 expression for cancer prognosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A meta-analysis of CXCL12 expression for cancer prognosis
2017
Overview
Background:
CXCL12 (SDF1) is reported to promote cancer progression in several preclinical models and this is corroborated by the analysis of human tissue specimens. However, the relationship between CXCL12 expression and cancer survival has not been systematically assessed.
Methods:
We conducted a systematic review and meta-analysis of studies that evaluated the association between CXCL12 expression and cancer survival.
Results:
Thirty-eight studies inclusive of 5807 patients were included in the analysis of overall, recurrence-free or cancer-specific survival, the majority of which were retrospective. The pooled hazard ratios (HRs) for overall and recurrence-free survival in patients with high CXCL12 expression were 1.39 (95% CI: 1.17–1.65,
P
=0.0002) and 1.12 (95% CI: 0.82–1.53,
P
=0.48) respectively, but with significant heterogeneity between studies. On subgroup analysis by cancer type, high CXCL12 expression was associated with reduced overall survival in patients with oesophagogastric (HR 2.08; 95% CI: 1.31–3.33,
P
=0.002), pancreatic (HR 1.54; 95% CI: 1.21–1.97,
P
=0.0005) and lung cancer (HR 1.37; 95% CI: 1.08–1.75,
P
=0.01), whereas in breast cancer patients high CXCL12 expression conferred an overall survival advantage (HR 0.5; 95% CI: 0.38–0.66,
P
<0.00001).
Conclusions:
Determination of CXCL12 expression has the potential to be of use as a cancer biomarker and adds prognostic information in various cancer types. Prospective or prospective–retrospective analyses of CXCL12 expression in clearly defined cancer cohorts are now required to advance our understanding of the relationship between CXCL12 expression and cancer outcome.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Antibodies, Monoclonal, Humanized
/ Biomedical and Life Sciences
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - mortality
/ Cancer
/ Chemokine CXCL12 - metabolism
/ Colorectal Neoplasms - metabolism
/ Colorectal Neoplasms - mortality
/ Esophageal Neoplasms - metabolism
/ Esophageal Neoplasms - mortality
/ Female
/ Humans
/ Male
/ Oncology
/ Pancreas
/ Pancreatic Neoplasms - metabolism
/ Pancreatic Neoplasms - mortality
/ Prostatic Neoplasms - metabolism
/ Prostatic Neoplasms - mortality
/ Stomach Neoplasms - metabolism
/ Stomach Neoplasms - mortality
/ Survival
